Target Synonym: DVS;IL1F;Interleukin;C9orf;IL-1F;IL33;C9orf26;DVS27;IL1F11;NF-HEV;NFEHEV;DVS27 related protein;IL-1F11;IL-33;Interleukin-1 family member 11;Interleukin-33;Nuclear factor from high endothelial venules;NFHEV;CHROMOSOME 9 OPEN READING FRAME 26;DKFZp586H0523;IL 1F11;IL 33;Interleukin 1 family member 11;Interleukin 33;INTERLEUKIN 33 NFHEV;Interleukin 33 precursor;Interleukin33;Interleukin-33 (109-270);NF HEV;Nuclear factor for high endothelial venules;OTTHUMP00000021041;RP11 575C20.2
Background: IL-33, also known as NF-HEV and DVS 27, is a 30 kDa proinflammatory protein that may also regulate gene transcription. DVS 27 was identifed as a gene that is upregulated in vasospastic cerebral arteries. NF-HEV was described as a nuclear factor that is preferentially expressed in the endothelial cells of high endothelial venules relative to endothelial cells from other tissues. IL-33 was identified based on sequence and structural homology with IL-1 family cytokines. DVS 27, NF-HEV, and IL-33 share 100% amino acid sequence identity. IL-33 is constitutively expressed in smooth muscle and airway epithelia. It is upregulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 alpha or IL-1 beta stimulation. Similar to IL-1, IL-33 can be cleaved in vitro by caspase-1, generating an N-terminal fragment that is slightly shorter than the C-terminal fragment. The N-terminal portion of full length IL-33 contains a predicted bipartite nuclear localization sequence and a homeodomain-like helix-turn-helix DNA binding domain. By immunofluorescence, full length IL-33 localizes to the nucleus in HUVECs and transfectants. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling through mast cell IL-1 R4/ST2L, a longtime orphan receptor involved in the augmentation of Th2 cell responses. A ternary signaling complex is formed by the subsequent association of IL-33 and ST2L with IL-1R AcP. Stimulation of Th2 polarized lymphocytes with mature IL-33 in vitro induces IL-5 and IL-13 secretion. In vivo administration of mature IL-33 promotes increased production of IL-5, IL-13, IgE, and IgA, as well as splenomegaly and inflammatory infiltration of mucosal tissues. Full length and mature human IL-33 share 52 ‑ 58% aa sequence identity with mouse and rat IL-33. Human IL-33 shares less than 20% aa sequence identity with other IL-1 family proteins.
Immunogen: Recombinant Human IL-33 Protein
Buffer: 0.2 μm filtered solution in PBS
Dilution: WB 1:500-1:2000;IP 0.5-2 μL/mg of lysate
Calculated MW: 31 kDa
Observed MW: 25 kDa
Deutsch
English
